Indonesia Imported US$2.3 Billion Worth of Pharmaceutical Ingredients from China in 2021

Throughout 2021, Indonesia's imports of pharmaceutical and health products originated mostly from China.

Based on data from the Central Statistics Agency (BPS), imports of pharmaceutical and health products from China reached US$2.33 billion, equivalent to Rp33.28 trillion (using an exchange rate of Rp14,269 per US$).

This value accounts for 69.41% of the total national imports of pharmaceutical and health products, which reached US$3.36 billion last year. The high value of these imports is in line with the large imports of vaccines, especially Covid-19 vaccines.

The next largest imports of pharmaceutical and health products came from the United States, reaching US$432.57 million in 2021 (12.87% share). This was followed by imports from Belgium with a value of US$221.32 million (6.59%), and from Spain with a value of US$191.64 million (5.7%).

Subsequently, there were imports from the Netherlands with a value of US$70.34 million (2.09%), Switzerland with US$54 million (1.61%), France with US$53.07 million (1.58%), and Puerto Rico with US$3.27 million (0.1%).

There were also imports of pharmaceutical and health products from Iran with a value of US$847,500 (0.01%), from Dominica with a value of US$481,630 (0.01%), and from Cuba with a value of US$441,960 (0.01%).